PE20011232A1 - Formas cristalinas de lopinavir - Google Patents

Formas cristalinas de lopinavir

Info

Publication number
PE20011232A1
PE20011232A1 PE2001000299A PE2001000299A PE20011232A1 PE 20011232 A1 PE20011232 A1 PE 20011232A1 PE 2001000299 A PE2001000299 A PE 2001000299A PE 2001000299 A PE2001000299 A PE 2001000299A PE 20011232 A1 PE20011232 A1 PE 20011232A1
Authority
PE
Peru
Prior art keywords
lopinavir
crystalline forms
amin
dimethylphenoxiacetyl
tetrahydropyrimid
Prior art date
Application number
PE2001000299A
Other languages
English (en)
Inventor
Daniel A Dickman
Sanjay Chemburkar
Rodger F Henry
Yuping Niu
William Porter
David Lechuga-Ballesteros
James J Fort
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27065762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20011232(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/793,536 external-priority patent/US6608198B2/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PE20011232A1 publication Critical patent/PE20011232A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A LA FORMA CRISTALINA HIDRATADA O SOLVATADA DE LOPINAVIR (2S,3S,5S)-2-(2,6-DIMETILFENOXIACETIL)AMIN-3-HIDROXI-5-(2-(1-TETRAHIDROPIRIMID-2-ONIL)-3-METILBUTANOL)AMIN-1,6-DIFENILHEXANO) DE FORMULA I CARACTERIZADA POR PRESENTAR UN ESPECTRO INFRARROJO; UN PATRON DE DIFRACCION DE RAYOS X. EL LOPINAVIR ES UN INHIBIDOR DE PROTEASA DEL VIH
PE2001000299A 2000-03-30 2001-03-30 Formas cristalinas de lopinavir PE20011232A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53825700A 2000-03-30 2000-03-30
US09/793,536 US6608198B2 (en) 2000-03-30 2001-02-27 Crystalline pharmaceutical

Publications (1)

Publication Number Publication Date
PE20011232A1 true PE20011232A1 (es) 2001-12-08

Family

ID=27065762

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000299A PE20011232A1 (es) 2000-03-30 2001-03-30 Formas cristalinas de lopinavir

Country Status (22)

Country Link
EP (1) EP1268442A2 (es)
JP (1) JP2003529592A (es)
KR (1) KR100773258B1 (es)
CN (2) CN1330639C (es)
AR (2) AR033360A1 (es)
AU (3) AU5092001A (es)
BG (1) BG107165A (es)
BR (1) BR0109433A (es)
CA (1) CA2403635A1 (es)
CZ (1) CZ20023529A3 (es)
HU (1) HUP0302675A3 (es)
IL (1) IL151551A0 (es)
MX (1) MXPA02009559A (es)
MY (1) MY128296A (es)
NO (1) NO325005B1 (es)
NZ (1) NZ521183A (es)
PE (1) PE20011232A1 (es)
PL (1) PL359727A1 (es)
SA (2) SA06270303B1 (es)
SK (1) SK14832002A3 (es)
TW (1) TWI284640B (es)
WO (1) WO2001074787A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608198B2 (en) 2000-03-30 2003-08-19 Abbott Laboratories Crystalline pharmaceutical
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
ES2459301T3 (es) * 2009-02-06 2014-05-08 Hetero Research Foundation Nuevos polimorfos de lopinavir
US8637449B2 (en) * 2009-08-27 2014-01-28 Merck Sharp & Dohme Corp. Processes for preparing protease inhibitors of hepatitis C virus
CN112830899A (zh) * 2021-01-18 2021-05-25 合肥华方医药科技有限公司 一种洛匹那韦新晶型及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound

Also Published As

Publication number Publication date
AR049560A2 (es) 2006-08-16
CN101066952A (zh) 2007-11-07
CZ20023529A3 (cs) 2003-02-12
BR0109433A (pt) 2004-08-10
NO20024679L (no) 2002-09-30
SA01220270B1 (ar) 2006-11-14
HUP0302675A3 (en) 2004-03-29
TWI284640B (en) 2007-08-01
NZ521183A (en) 2004-03-26
WO2001074787A2 (en) 2001-10-11
CA2403635A1 (en) 2001-10-11
MY128296A (en) 2007-01-31
AU2006222711A1 (en) 2006-10-19
NO325005B1 (no) 2008-01-14
WO2001074787A3 (en) 2002-02-07
SA06270303B1 (ar) 2009-08-02
JP2003529592A (ja) 2003-10-07
IL151551A0 (en) 2003-04-10
MXPA02009559A (es) 2003-05-21
CN1422259A (zh) 2003-06-04
CN1330639C (zh) 2007-08-08
AU2001250920B2 (en) 2006-06-29
KR20030011807A (ko) 2003-02-11
EP1268442A2 (en) 2003-01-02
NO20024679D0 (no) 2002-09-30
PL359727A1 (en) 2004-09-06
KR100773258B1 (ko) 2007-11-05
BG107165A (bg) 2003-07-31
AU5092001A (en) 2001-10-15
SK14832002A3 (sk) 2003-02-04
AR033360A1 (es) 2003-12-17
HUP0302675A2 (hu) 2003-12-29

Similar Documents

Publication Publication Date Title
CY1113508T1 (el) Παραγωγα 2,4-διαμινοπυριμιδινης
SE0100902D0 (sv) Compounds
NO950533D0 (no) Hydroksyetylaminosulfonamider som er nyttige som retrovirale proteasehemmere
IS7556A (is) Uppsöfnun í frumu á phosphomate hliðstæðum a HIV próteasa hindrandi efnasamböndum
CY1113578T1 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
SE0100903D0 (sv) Compounds
RS51444B (sr) JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
CY1113657T1 (el) Νεα παραγωγα βενζοφαινονης ή αλατα αυτων
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
NO20052787L (no) N-alkyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
ECSP045221A (es) Sales de valsartan
ATE403429T1 (de) Spiropyrazol-verbindungen
IS7893A (is) Perindópríl
EA200200819A1 (ru) Кристаллическая форма ii линезолида
ATE382604T1 (de) Aminosäure-derivate als hiv aspartyl-protease- inhibitoren
ATE368645T1 (de) Aminosäurederivate als hiv-protease-inhibitoren
DE60218064D1 (de) Neues peptid mit angiotensinkonvertase hemmender wirkung
DE602004024830D1 (de) Die hiv-protease inhibierende sulfonamide
PE20011232A1 (es) Formas cristalinas de lopinavir
UY26416A1 (es) Compuestos
BR0114709A (pt) Métodos para a preparação de bifenil isoxazol sulfonamidas
HRP20030653B1 (en) Novel benzoylguanidine salt
ES2172918T3 (es) Derivado de piperidinilmetiloxazolidinona.
UY26251A1 (es) Forma cristalina iii de la n- (4-(5- dimetilaminonaftalen-1- sulfonilamino) fenil) -3 - hidroxi-2, 2- dimetilpropionamida
TW200519071A (en) 3-aryl-2-cyano-3-hydroxy-acrylic acid derivatives

Legal Events

Date Code Title Description
FA Abandonment or withdrawal